GSK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that GSK plc Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
stocknews12h
3 Precision Medicine Stocks That Could Transform Healthcare
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
manilatimes2d
C3i Center, a Canadian company, receives approval from the EMA to manufacture cell therapy products for the European market
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to ...
Merck wins EU nod for Welireg against two kidney cancer indications
Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
The American Journal of Managed Care1d
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
PharmiWeb21h
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Managed Healthcare Executive1d
FDA, EMA See Differences in Cell and Gene Therapy Trial Data
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
EURACTIV4d
Smaller EU states risk being left behind in critical medicines market, says Belgian MEP Sommen
Belgian MEP Liesbet Sommen spoke with Euractiv about critical medicines shortages, EU Pharma Package progress, and SANT's evolving role.